Do analysts prefer REVB or IMAC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Revelation Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 IMAC 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts recommend IMAC or FBLG?

FibroBiologics has a consensus price target of $74.00, indicating a potential upside of 9,086.84%. Given FibroBiologics' stronger consensus rating and higher probable upside, analysts plainly believe FibroBiologics is more favorable than IMAC. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IMAC 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 FibroBiologics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is IMAC or FBLG more profitable?

FibroBiologics has a net margin of 0.00% compared to IMAC's net margin of -75.40%. IMAC's return on equity of -52.17% beat FibroBiologics' return on equity. Company Net Margins Return on Equity Return on Assets IMAC -75.40% -52.17% -34.51% FibroBiologics N/A -767.07% -195.56%

Does the media favor IMAC or FBLG?

In the previous week, FibroBiologics had 1 more articles in the media than IMAC. MarketBeat recorded 2 mentions for FibroBiologics and 1 mentions for IMAC. IMAC's average media sentiment score of 0.00 equaled FibroBiologics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IMAC 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral FibroBiologics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate ENSC or IMAC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ensysce Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 IMAC 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is ENSC or IMAC more profitable?

IMAC has a net margin of -75.40% compared to Ensysce Biosciences' net margin of -250.39%. IMAC's return on equity of -52.17% beat Ensysce Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Ensysce Biosciences -250.39% -766.45% -256.59% IMAC -75.40% -52.17% -34.51%

Do analysts recommend IMAC or GRI?

GRI Bio has a consensus target price of $32.00, suggesting a potential upside of 1,611.23%. Given GRI Bio's stronger consensus rating and higher probable upside, analysts plainly believe GRI Bio is more favorable than IMAC. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IMAC 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 GRI Bio 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher valuation and earnings, IMAC or GRI?

IMAC has higher revenue and earnings than GRI Bio. IMAC is trading at a lower price-to-earnings ratio than GRI Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IMAC $15.22M 0.07 -$10.54M -$0.27 N/A GRI Bio N/A N/A -$11.96M -$74.16 N/A

Is IMAC or GRI more profitable?

GRI Bio has a net margin of 0.00% compared to IMAC's net margin of -75.40%. IMAC's return on equity of -52.17% beat GRI Bio's return on equity. Company Net Margins Return on Equity Return on Assets IMAC -75.40% -52.17% -34.51% GRI Bio N/A -199.52% -143.23%

Does the media favor IMAC or GRI?

In the previous week, GRI Bio had 1 more articles in the media than IMAC. MarketBeat recorded 2 mentions for GRI Bio and 1 mentions for IMAC. GRI Bio's average media sentiment score of 0.57 beat IMAC's score of 0.00 indicating that GRI Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IMAC 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral GRI Bio 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend IMAC or GOVX?

GeoVax Labs has a consensus target price of $150.00, indicating a potential upside of 11,263.64%. Given GeoVax Labs' stronger consensus rating and higher probable upside, analysts clearly believe GeoVax Labs is more favorable than IMAC. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IMAC 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 GeoVax Labs 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has preferable earnings and valuation, IMAC or GOVX?

IMAC has higher revenue and earnings than GeoVax Labs. IMAC is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IMAC $15.22M 0.07 -$10.54M -$0.27 N/A GeoVax Labs $2.49M 1.84 -$21.47M -$19.12 N/A

Is IMAC or GOVX more profitable?

GeoVax Labs has a net margin of 0.00% compared to IMAC's net margin of -75.40%. IMAC's return on equity of -52.17% beat GeoVax Labs' return on equity. Company Net Margins Return on Equity Return on Assets IMAC -75.40% -52.17% -34.51% GeoVax Labs N/A -709.52% -399.33%

Does the media favor IMAC or GOVX?

In the previous week, GeoVax Labs had 1 more articles in the media than IMAC. MarketBeat recorded 2 mentions for GeoVax Labs and 1 mentions for IMAC. IMAC's average media sentiment score of 0.00 equaled GeoVax Labs'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IMAC 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral GeoVax Labs 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

IMAC (IMAC) Competitors

$0.04 0.00 (0.00%)

As of 06/18/2026

Compare

IMAC vs. REVB, FBLG, ENSC, GRI, and GOVX

Should you buy IMAC stock or one of its competitors? MarketBeat compares IMAC with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with IMAC include Revelation Biosciences (REVB), FibroBiologics (FBLG), Ensysce Biosciences (ENSC), GRI Bio (GRI), and GeoVax Labs (GOVX). These companies are all part of the "medical" sector.

How does IMAC compare to Revelation Biosciences?

Revelation Biosciences (NASDAQ:REVB) and IMAC (NASDAQ:IMAC) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, media sentiment, analyst recommendations and earnings.

In the previous week, IMAC had 1 more articles in the media than Revelation Biosciences. MarketBeat recorded 1 mentions for IMAC and 0 mentions for Revelation Biosciences. Revelation Biosciences' average media sentiment score of 0.00 equaled IMAC'saverage media sentiment score.

Company	Overall Sentiment
Revelation Biosciences	Neutral
IMAC	Neutral

Revelation Biosciences has a beta of -0.09, indicating that its stock price is 109% less volatile than the broader market. Comparatively, IMAC has a beta of -0.88, indicating that its stock price is 188% less volatile than the broader market.

Revelation Biosciences has higher earnings, but lower revenue than IMAC. IMAC is trading at a lower price-to-earnings ratio than Revelation Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revelation Biosciences	N/A	N/A	-$8.91M	-$39.48	N/A
IMAC	$15.22M	0.07	-$10.54M	-$0.27	N/A

Revelation Biosciences has a net margin of 0.00% compared to IMAC's net margin of -75.40%. IMAC's return on equity of -52.17% beat Revelation Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revelation Biosciences	N/A	-107.65%	-87.98%
IMAC	-75.40%	-52.17%	-34.51%

12.8% of Revelation Biosciences shares are held by institutional investors. Comparatively, 24.3% of IMAC shares are held by institutional investors. 4.8% of Revelation Biosciences shares are held by company insiders. Comparatively, 10.0% of IMAC shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revelation Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
IMAC	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

IMAC beats Revelation Biosciences on 7 of the 12 factors compared between the two stocks.

How does IMAC compare to FibroBiologics?

IMAC (NASDAQ:IMAC) and FibroBiologics (NASDAQ:FBLG) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, valuation, dividends, profitability and analyst recommendations.

FibroBiologics has a net margin of 0.00% compared to IMAC's net margin of -75.40%. IMAC's return on equity of -52.17% beat FibroBiologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IMAC	-75.40%	-52.17%	-34.51%
FibroBiologics	N/A	-767.07%	-195.56%

IMAC has a beta of -0.88, meaning that its stock price is 188% less volatile than the broader market. Comparatively, FibroBiologics has a beta of 1.13, meaning that its stock price is 13% more volatile than the broader market.

FibroBiologics has a consensus price target of $74.00, indicating a potential upside of 9,086.84%. Given FibroBiologics' stronger consensus rating and higher probable upside, analysts plainly believe FibroBiologics is more favorable than IMAC.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IMAC	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
FibroBiologics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

IMAC has higher revenue and earnings than FibroBiologics. IMAC is trading at a lower price-to-earnings ratio than FibroBiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IMAC	$15.22M	0.07	-$10.54M	-$0.27	N/A
FibroBiologics	N/A	N/A	-$18.65M	-$6.93	N/A

In the previous week, FibroBiologics had 1 more articles in the media than IMAC. MarketBeat recorded 2 mentions for FibroBiologics and 1 mentions for IMAC. IMAC's average media sentiment score of 0.00 equaled FibroBiologics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IMAC	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
FibroBiologics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

24.3% of IMAC shares are owned by institutional investors. 10.0% of IMAC shares are owned by insiders. Comparatively, 9.3% of FibroBiologics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

IMAC and FibroBiologics tied by winning 7 of the 14 factors compared between the two stocks.

How does IMAC compare to Ensysce Biosciences?

Ensysce Biosciences (NASDAQ:ENSC) and IMAC (NASDAQ:IMAC) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings.

Ensysce Biosciences has a beta of 0.83, suggesting that its share price is 17% less volatile than the broader market. Comparatively, IMAC has a beta of -0.88, suggesting that its share price is 188% less volatile than the broader market.

IMAC has a net margin of -75.40% compared to Ensysce Biosciences' net margin of -250.39%. IMAC's return on equity of -52.17% beat Ensysce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ensysce Biosciences	-250.39%	-766.45%	-256.59%
IMAC	-75.40%	-52.17%	-34.51%

5.6% of Ensysce Biosciences shares are owned by institutional investors. Comparatively, 24.3% of IMAC shares are owned by institutional investors. 2.8% of Ensysce Biosciences shares are owned by insiders. Comparatively, 10.0% of IMAC shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Ensysce Biosciences has higher earnings, but lower revenue than IMAC. IMAC is trading at a lower price-to-earnings ratio than Ensysce Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ensysce Biosciences	$5.07M	0.83	-$10.18M	-$3.35	N/A
IMAC	$15.22M	0.07	-$10.54M	-$0.27	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ensysce Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
IMAC	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, IMAC had 1 more articles in the media than Ensysce Biosciences. MarketBeat recorded 1 mentions for IMAC and 0 mentions for Ensysce Biosciences. Ensysce Biosciences' average media sentiment score of 0.00 equaled IMAC'saverage media sentiment score.

Company	Overall Sentiment
Ensysce Biosciences	Neutral
IMAC	Neutral

Summary

IMAC beats Ensysce Biosciences on 8 of the 13 factors compared between the two stocks.

How does IMAC compare to GRI Bio?

IMAC (NASDAQ:IMAC) and GRI Bio (NASDAQ:GRI) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, risk, valuation and profitability.

GRI Bio has a consensus target price of $32.00, suggesting a potential upside of 1,611.23%. Given GRI Bio's stronger consensus rating and higher probable upside, analysts plainly believe GRI Bio is more favorable than IMAC.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IMAC	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
GRI Bio	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, GRI Bio had 1 more articles in the media than IMAC. MarketBeat recorded 2 mentions for GRI Bio and 1 mentions for IMAC. GRI Bio's average media sentiment score of 0.57 beat IMAC's score of 0.00 indicating that GRI Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IMAC	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
GRI Bio	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

GRI Bio has a net margin of 0.00% compared to IMAC's net margin of -75.40%. IMAC's return on equity of -52.17% beat GRI Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IMAC	-75.40%	-52.17%	-34.51%
GRI Bio	N/A	-199.52%	-143.23%

IMAC has a beta of -0.88, suggesting that its share price is 188% less volatile than the broader market. Comparatively, GRI Bio has a beta of -1.17, suggesting that its share price is 217% less volatile than the broader market.

IMAC has higher revenue and earnings than GRI Bio. IMAC is trading at a lower price-to-earnings ratio than GRI Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IMAC	$15.22M	0.07	-$10.54M	-$0.27	N/A
GRI Bio	N/A	N/A	-$11.96M	-$74.16	N/A

24.3% of IMAC shares are owned by institutional investors. Comparatively, 34.0% of GRI Bio shares are owned by institutional investors. 10.0% of IMAC shares are owned by company insiders. Comparatively, 8.7% of GRI Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

GRI Bio beats IMAC on 8 of the 15 factors compared between the two stocks.

How does IMAC compare to GeoVax Labs?

IMAC (NASDAQ:IMAC) and GeoVax Labs (NASDAQ:GOVX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, earnings, analyst recommendations, institutional ownership, risk and valuation.

GeoVax Labs has a consensus target price of $150.00, indicating a potential upside of 11,263.64%. Given GeoVax Labs' stronger consensus rating and higher probable upside, analysts clearly believe GeoVax Labs is more favorable than IMAC.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IMAC	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
GeoVax Labs	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

In the previous week, GeoVax Labs had 1 more articles in the media than IMAC. MarketBeat recorded 2 mentions for GeoVax Labs and 1 mentions for IMAC. IMAC's average media sentiment score of 0.00 equaled GeoVax Labs'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IMAC	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
GeoVax Labs	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

GeoVax Labs has a net margin of 0.00% compared to IMAC's net margin of -75.40%. IMAC's return on equity of -52.17% beat GeoVax Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IMAC	-75.40%	-52.17%	-34.51%
GeoVax Labs	N/A	-709.52%	-399.33%

IMAC has a beta of -0.88, suggesting that its share price is 188% less volatile than the broader market. Comparatively, GeoVax Labs has a beta of 3.62, suggesting that its share price is 262% more volatile than the broader market.

IMAC has higher revenue and earnings than GeoVax Labs. IMAC is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IMAC	$15.22M	0.07	-$10.54M	-$0.27	N/A
GeoVax Labs	$2.49M	1.84	-$21.47M	-$19.12	N/A

24.3% of IMAC shares are held by institutional investors. Comparatively, 6.1% of GeoVax Labs shares are held by institutional investors. 10.0% of IMAC shares are held by company insiders. Comparatively, 0.7% of GeoVax Labs shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

IMAC and GeoVax Labs tied by winning 7 of the 14 factors compared between the two stocks.

Get IMAC News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMAC vs. The Competition

Export

Metric	IMAC	Specialty Outpatient Clinics Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.06M	$932.00K	$6.42B	$12.38B
Dividend Yield	N/A	N/A	2.68%	5.81%
P/E Ratio	-0.15	N/A	24.82	24.35
Price / Sales	0.07	0.07	571.82	128.89
Price / Cash	N/A	N/A	27.92	37.84
Price / Book	0.06	0.06	10.85	6.58
Net Income	-$10.54M	-$10.54M	$3.56B	$336.75M
7 Day Performance	N/A	N/A	0.70%	-0.49%
1 Month Performance	N/A	N/A	0.29%	1.56%
1 Year Performance	N/A	N/A	30.68%	33.78%

IMAC Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMAC IMAC	N/A	$0.04 flat	N/A	-20.0%	$1.06M	$15.22M	N/A	106	News Coverage Gap Up
REVB Revelation Biosciences	0.9719 of 5 stars	$0.98 -8.4%	N/A	-89.1%	$4.18M	N/A	N/A	10
FBLG FibroBiologics	2.7435 of 5 stars	$0.77 -3.7%	$74.00 +9,507.9%	-94.5%	$4.17M	N/A	N/A	10	News Coverage Gap Up
ENSC Ensysce Biosciences	0.7973 of 5 stars	$0.28 +3.0%	N/A	-86.2%	$4.15M	$5.07M	N/A	10
GRI GRI Bio	2.4507 of 5 stars	$1.88 -19.1%	$32.00 +1,603.9%	-94.9%	$4.11M	N/A	N/A	1	Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMAC) was last updated on 6/22/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

IMAC (IMAC) Competitors

IMAC vs. REVB, FBLG, ENSC, GRI, and GOVX

How does IMAC compare to Revelation Biosciences?

Summary

How does IMAC compare to FibroBiologics?

Summary

How does IMAC compare to Ensysce Biosciences?

Summary

How does IMAC compare to GRI Bio?

Summary

How does IMAC compare to GeoVax Labs?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMAC vs. The Competition

IMAC Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

IMAC (IMAC) Competitors

IMAC vs. REVB, FBLG, ENSC, GRI, and GOVX

How does IMAC compare to Revelation Biosciences?

Does the media prefer REVB or IMAC?

Which has more risk & volatility, REVB or IMAC?

Which has preferable valuation and earnings, REVB or IMAC?

Is REVB or IMAC more profitable?

Do insiders and institutionals believe in REVB or IMAC?

Do analysts prefer REVB or IMAC?

Summary

How does IMAC compare to FibroBiologics?

Is IMAC or FBLG more profitable?

Which has more volatility and risk, IMAC or FBLG?

Do analysts recommend IMAC or FBLG?

Which has better valuation and earnings, IMAC or FBLG?

Does the media favor IMAC or FBLG?

Do institutionals & insiders believe in IMAC or FBLG?

Summary

How does IMAC compare to Ensysce Biosciences?

Which has more volatility and risk, ENSC or IMAC?

Is ENSC or IMAC more profitable?

Do institutionals and insiders hold more shares of ENSC or IMAC?

Which has stronger valuation & earnings, ENSC or IMAC?

Do analysts rate ENSC or IMAC?

Does the media refer more to ENSC or IMAC?

Summary

How does IMAC compare to GRI Bio?

Do analysts recommend IMAC or GRI?

Does the media favor IMAC or GRI?

Is IMAC or GRI more profitable?

Which has more volatility and risk, IMAC or GRI?

Which has higher valuation and earnings, IMAC or GRI?

Do institutionals & insiders have more ownership in IMAC or GRI?

Summary

How does IMAC compare to GeoVax Labs?

Do analysts recommend IMAC or GOVX?

Does the media favor IMAC or GOVX?

Is IMAC or GOVX more profitable?

Which has more risk & volatility, IMAC or GOVX?

Which has preferable earnings and valuation, IMAC or GOVX?

Do insiders & institutionals believe in IMAC or GOVX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMAC vs. The Competition

IMAC Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools